Increased Peri-implant Keratinized Mucosal Thickness at Different Operative Times
NCT ID: NCT04683991
Last Updated: 2022-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
34 participants
INTERVENTIONAL
2021-05-27
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is considered that autogenous soft tissue graft is the most reliable technology to augment keratinized mucosa. Subepithelial connective tissue graft (SCTG) is a mucogingival surgery that transplant autologous free connective tissue under the pedicled semi thick flap to augment keratinized mucosa. It can effectively increase the thickness of soft tissue, cover the exposed implant, and reconstruct the interdental papilla. It is the gold standard for peri-implant soft tissue agumentation. Keratinized mucosal thickening surgery may be done prior to the surgical phase, after the surgical phase, before loading, or even after loading. It is believed that keratinized mucosal thickening at the same time of implantation can effectively reduce the possibility of mucosal recession after implantation, reduce the amount of marginal bone absorption in the process of osseointegration, which is conducive to maintaining the long-term stability of the implant. For the sake of clear clinical vision and convenient operation, clinicians often choose to thicken the keratinized mucosa during the secondary operation, and also obtain good postoperative effect. However, after the completion of the final repair, the keratinized mucosa thickening surgery increases the difficulty of operation and the technical requirements for the operator. In clinical practice, it is rarely selected to perform keratinized mucosal thickening at this time. At present, the effectiveness of timing on the outcome of soft tissue augmentation is still debated, and, most importantly, a direct comparison between simultaneous and staged procedures remains underexplored.
Therefore, this clinical trial is to prospectively compare the clinical efficacy of simultaneous versus delayed timing of soft tissue augmentation by SCTG placement around single implants, by evaluating the peri-implant marginal bone level change and soft tissue change, so as to provide reference for the formulation of clinical treatment plan and the selection of the best operation time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of the Adequacy of Keratinized Mucosa on Peri-implant Tissue Health and Patient-reported Outcomes
NCT07124416
Predictive Value of Reduced Keratinized Mucosa on the Secondary Prevention of Peri-implant Mucositis and Periimplantitis in Patients Attending Regular Supportive Peri-implant Care. A Longitudinal Analysis
NCT05804760
Influence of Keratinized Mucosa on Dental Implants With Mucositis
NCT04874467
Lingual Keratinized Tissue in Fully Edentulous Patients and Its Impact on Implant Health
NCT06166017
The Impact of Peri-implant Soft Tissue Properties on Patient-reported and Clinically Assessed Outcomes
NCT03396536
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treatment group 1
At the same time of implant implantation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
Subepithelial connective tissue graft
A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
treatment group 2
During the second stage operation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
Subepithelial connective tissue graft
A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Subepithelial connective tissue graft
A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The thickness of keratinized mucosa where the posterior tooth is missing is less than 2 mm;
* Full-mouth plaque score (FMPS) \< 20% (measured at four sites per tooth) and bleeding on probing score (BOP%) ≤25% (measured at six sites per tooth);
* Periodontal condition is stable, no probing depths ≥5 mm;
* No previous soft tissue augmentation procedure at experimental site;
* The patient has signed informed consent and accepts the operation of subepithelial connective tissue transplantation.
Exclusion Criteria
* Patients with uncontrolled diabetes;
* Patients with insufficient oral hygiene and Untreated periodontitis;
* Pregnant or lactating women;
* Smoker;
* Patients with long-term (\> 6 months) use of glucocorticoids;
* History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 5 years;
* Patients with severe cardiovascular problems;
* Patients with uncontrolled infectious or metabolic diseases;
* Patients with substance abuse.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weilian Sun
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Oral Medicine, the Second Affiliated Hospital, School of Medicine Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Weilian Sun
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-782
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.